(S046) Prospective Evaluation of Stereotactic Radiation Therapy for Spinal Metastases in the Postoperative Setting: A Secondary Analysis of Mature Phase I/II Trials

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

On univariate and multivariate competing risks analysis, sarcoma histology and larger preoperative tumor volumes were significantly associated with worse local control. Radioresistant histology and Karnofsky performance status were significant predictors for OS on multivariate analysis.

Randa Tao, MD, Andrew J. Bishop, Zachary Brownlee, Pamela K. Allen, Stephen H. Settle, MD, PhD,  Eric L. Chang, MD, Xin Wang, PhD, Behrang Amini, MD, PhD, Nizar Tannir, MD, Laurence D. Rhines, MD, Paul D. Brown, MD, Amol J. Ghia, MD; UT MD Anderson Cancer Center; USC Norris Cancer Hospital

PURPOSE: To evaluate the outcomes of patients treated on prospective phase I/II protocols with postoperative stereotactic body radiation therapy (SBRT) and identify the associated prognostic variables.        

MATERIALS AND METHODS: In two prospective phase I/II studies, 76 patients with 81 tumors were treated with SBRT for spinal metastases between 2002 and 2010. All patients underwent SBRT after spine surgery, which included laminectomy, vertebrectomy, vertebroplasty, and a combination of these techniques. Renal cell carcinoma was the most common histology represented (n = 39; 51%), followed by sarcomas (n = 14; 18%). Thirty-six patients (47%) were treated with prior conventional radiation to the spine (median dose: 30 Gy). Patients were followed with spinal magnetic resonance imaging  studies to determine local control (LC) and spinal progression-free survival (PFS). Pain and other symptom data were collected prospectively to determine treatment response and toxicity.  

RESULTS: The median follow-up was 29 months (range: 1–145 mo) for all patients and 75 months for living patients (range: 6–145 mo). The actuarial 1-year rate of LC was 82%, adjacent vertebral body control was 84%, spinal PFS was 65%, and overall survival (OS) was 76% (median: 29 mo). On univariate and multivariate competing risks analysis, sarcoma histology (subhazard ratio [SHR], 2.36 [95% CI, 1.03–5.4]; P = .043) and larger preoperative tumor volumes (SHR, 1.01 [95% CI, 1.0–1.01]; P = .006) were significantly associated with worse LC. Radioresistant histology and Karnofsky performance status were significant predictors for OS on multivariate analysis. There were no differences in LC between patients treated with different surgical techniques or different preoperative or postoperative Bilsky grades. There were no grade ≥ 3 neurologic toxicities.

Proceedings of the 98th Annual Meeting of the American Radium Society -americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
Related Content